November 28, 2017 / 12:12 PM / in 19 days

BRIEF-Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Study Of VK5211 In Patients Recovering From Hip Fracture

Nov 28 (Reuters) - Viking Therapeutics Inc:

* VIKING THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF VK5211 IN PATIENTS RECOVERING FROM HIP FRACTURE

* VIKING THERAPEUTICS - DATA SHOWED TRIAL ACHIEVED PRIMARY ENDPOINT FOLLOWING TREATMENT WITH VK5211 AS COMPARED TO PLACEBO

* ‍STUDY ALSO ACHIEVED SECONDARY ENDPOINTS FOR ALL DOSES OF VK5211, COMPARED TO PLACEBO​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below